ecropolis

Association between SARS-CoV-2 variants and frequency of acute symptoms: Analysis of a multi-institutional prospective cohort study – December 20, 2020 – June 20, 2022 | Development of a Definition of Postacute Sequelae of SARS-CoV-2 Infection | Pfizer’s PAXLOVID™ Receiving FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19 |
Potential for Recurrent Mpox Outbreaks Among Gay, Bisexual, and Other Men Who Have Sex with Men — United States, 2023 | A Prospective Study of Key Correlates for Household Transmission of SARS-CoV-2 | Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalized with COVID-19 (COVASP): a pragmatic, cluster-randomized, non-inferiority trial |
COVID-19 and Risk for Mental Disorders Among Adults in Denmark

FDA voted in favor of approving the Abrysvo vaccine | Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years |
Statement on the antigen composition of COVID-19 vaccines |
Canine Olfactory Detection of SARS-CoV-2-Infected Humans | CDC HIV surveillance report

Risk of post-acute sequelae of SARS-CoV-2 infection associated with pre-coronavirus disease obstructive sleep apnea diagnoses: an electronic health record-based analysis from the RECOVER initiative | Trajectories of the evolution of post COVID-19 condition, up to two years after symptoms onset | Virus variant specific clinical performance of a SARS-CoV-2 rapid antigen test with focus on omicron VOC. | COVID-19 mortality among selective serotonin reuptake inhibitor users – Results from a nationwide cohort | Efficacy of cognitive behavioral therapy targeting severe fatigue following COVID-19: results of a randomized controlled trial

Impact of SARS-CoV-2 Variants on Inpatient Clinical Outcome |
Immunogenicity and tolerability of a bivalent virus-like particle norovirus vaccine candidate in children from 6 months up to 4 years of age: A phase 2 randomized, double-blind trial |
An influenza hemagglutinin stem nanoparticle vaccine induces cross-group 1 neutralizing antibodies in healthy adults | Targeted Vaccine Messaging to Promote COVID-19 Vaccines for Children and Youth |
Vaccines and Related Biological Products Advisory Committee Meeting June 15, 2023 Announcement | Gut microbiota‐derived synbiotic formula (SIM01) as a novel adjuvant therapy for COVID‐19: An open‐label pilot study |
COVID-19 Surveillance After Expiration of the Public Health Emergency Declaration |
Provisional Mortality Data |
Prevalence of Post-Coronavirus Disease Condition 12 Weeks After Omicron Infection Compared With Negative Controls and Association With Vaccination Status

Long COVID brain fog and muscle pain are associated with longer time to clearance of SARS-CoV-2 RNA | U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States | Vaccination with BCG-Denmark did not result in a lower risk of Covid-19 among health care workers than placebo |NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial | Comparative effectiveness of the sars-CoV-2 vaccines during Delta dominance | Clinical Outcomes Following Treatment for COVID-19 | Real-life experience with remdesivir for treatment of COVID-19 among older adults: a multicentre retrospective study | Association between SARS-CoV-2 and metagenomic content of samples from the Huanan Seafood Market | Researchers disagree over how bad it is to be reinfected, and whether COVID-19 can cause lasting changes to the immune system | Virtual Care and Emergency Department Use During the COVID-19 Pandemic Among Patients of Family Physicians in Ontario, Canada | Assessment of Gender-Specific COVID-19 Case Fatality Risk per Malignant Neoplasm Type | Timing of intubation and ICU mortality in COVID-19 patients

SARS-CoV-2 Reinfection and Severity of the Disease: A Systematic Review and Meta-Analysis | Completeness and Spin of medRxiv Preprint and Associated Published Abstracts of COVID-19 Randomized Clinical Trials | Risk of new-onset Long Covid following reinfection with SARS-CoV-2: community-based cohort study |
Low vitamin D levels are associated with Long COVID syndrome in COVID-19 survivors | Effectiveness of Coronavirus Disease 2019 (COVID-19) Bivalent Vaccine | Molnupiravir and risk of post-acute sequelae of COVID-19 | Clinical experience with the α2A-adrenoceptor agonist, guanfacine, and N-acetylcysteine for the treatment of cognitive deficits in “Long-COVID19” | Lessons Learned From a COVID-19 Dog Screening Pilot in California K-12 Schools

Update on Vaccine-Derived Poliovirus Outbreaks | Sleep Disturbance Severity and Correlates |
Two individuals with potential monkeypox virus reinfection | Risk of autoimmune diseases in patients |
FDA Authorizes Changes to Simplify Use of Bivalent mRNA COVID-19 Vaccines | SARS-CoV-2 neutralizing antibodies | Durability of Bivalent Boosters against Omicron Subvariants | Nirmatrelvir and risk of hospital admission or death in adults | Evolving Real-World Effectiveness of Monoclonal Antibodies | Effect of Angiotensin-Converting Enzyme Inhibitor | Efficacy and Safety of Anakinra Plus Standard | Higher dose corticosteroids in patients admitted to hospital | Risk of Death in Patients Hospitalized for COVID-19 | Recent French mpox cluster includes fully vaccinated patients | Epidemiologic and Clinical Features of Mpox-Associated Deaths | SARS-CoV-2 During Omicron Variant Predominance | Severe Maternal Morbidity and Mortality of Pregnant Patients | Sickness presenteeism in healthcare workers | Ventilation Improvements Among K–12 Public School Districts | Risk factors and vectors for SARS-CoV-2 household transmission | Definition of Post–COVID-19 Condition

Prevalence and Characteristics Associated With Post–COVID-19 Condition | The Breadth of the Neutralizing Antibody Response to Original SARS-CoV-2 Infection |
Pathogenesis Underlying Neurological Manifestations of Long COVID Syndrome | Vaccine effectiveness against hospitalization among adolescent cases |
Effectiveness of BNT162b2 after extending the primary series dosing interval in children | Within-host genetic diversity of SARS-CoV-2 |
Live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants | Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection |
COVID-19 convalescent plasma utilization in the United States |
FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19 | Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients |
Anti-C5a antibody (vilobelimab) therapy for critically ill patients |
Triple combination therapy with two antivirals | Adeno-associated virus type 2 in US children | Genomic investigations of unexplained acute hepatitis in children | Surveillance of SARS-CoV-2 at the Huanan Seafood Market